8
Participants
Start Date
July 4, 2018
Primary Completion Date
March 18, 2019
Study Completion Date
November 26, 2020
Vilaprisan (BAY1002670)
Intake orally, once daily
Matching Placebo
Intake orally, once daily
Universitätsklinikum AKH Wien, Vienna
Kepler Universitätsklinikum Campus IV, Linz
Medizinische Universität Graz, Graz
KABEG Landeskrankenhaus Villach, Villach
Office of Dr. James A. Simon, MD, Washington D.C.
Unified Women's Clinical Research, Winston-Salem
Satakunnan keskussairaala, Pori
Unified Women's Clinical Research - Morehead City, Morehead City
Solutions Through Advanced Research, Inc., Jacksonville
Helix Biomedics, LLC, Boynton Beach
A.O.U.I. Verona, Verona
Southern Clinical Research Associates LLC, Metairie
Queen's University, Kingston
Ottawa Hospital-Riverside Campus, Ottawa
Clinique OVO, Montreal
Gynekologie MEDA s.r.o., Brno
GynCare MUDr. Michael Svec s.r.o., Pilsen
VL-Medi Oy, Helsinki
Tokeidai Memorial Clinic, Sapporo
Ishikawa Prefectural Central Hospital, Kanazawa
Japanese Red Cross Kumamoto Hospital, Kumamoto
Toyama Prefectural Central Hospital, Toyama
Centrum Medyczne Chodzki, Lublin
Lead Sponsor
Bayer
INDUSTRY